Age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Age-standardized prevalence rates of gynecological diseases across 21 GBD regions, by SDI, from 1990 to 2021. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Prevalence and trends of gynecological diseases (GDs) among women of childbearing age, by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage changes in the prevalence rate of specific gynecological diseases from 1990 to 2021, categorized by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Prevalence of gynecological diseases (GDs) among women of childbearing age in 2021, along with their changes from 1990 to 2021, and the contribution of each GD to the overall preva... by Xiaofeng He (2618752)

Subjects:

The global prevalence of gynecological diseases among women aged 15-49 years in 1990 and 2021, along with the trends and changes observed between these years. by Xiaofeng He (2618752)

Subjects:

Tgfβ-1 levels drives liver collagen deposition and pJak2-pStat3 signaling in obese <i>mMgat2</i> and <i>HuMgat2</i> mice. by J. Jose Corbalan (22439198)

Subjects:

(A) Beta-diversity non-metric multidimensional scaling (NMDS) analysis at genus level, and (B) LEfSe for bacterial species biomarkers representing control vs. stroke groups. by Duangnapa Roongpiboonsopit (12829198)

Subjects:

Geometric mean anti-<i>Na</i>-GST-1 IgG subclass levels over time. by David J. Diemert (8135568)

Subjects:

Effects of NMRAL1 siRNA transfection on the expression of inflammatory cytokines in RAW264.7 macrophages. by Miao Cheng (4348510)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects:

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects:

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects:

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects:

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects:

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects:

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects:

ssGSEA is employed to analyze immune infiltration in IS and OSA. by Zhe Wu (582498)

Subjects:

Limma differential analysis results for IS and OSA. by Zhe Wu (582498)

Subjects: